Table 2 Switching pattern of bDMARDs or tsDMARDs in each trajectory group
|  | Group 1 (N = 319) | Group 2 (N = 36) | Group 3 (N = 290) | Group 4 (N = 43) |
|---|---|---|---|---|
Number of switches for bDMARDs or tsDMARDs, n (%) | ||||
 Never | 276 (86.5) | 19 (52.8) | 146 (50.3) | 11 (25.6) |
 Once | 40 (12.5) | 11 (30.6) | 115 (39.7) | 14 (32.6) |
 Twice | 3 (0.9) | 5 (13.9) | 26 (9.0) | 11 (25.6) |
 Three times | 0 (0.0) | 1 (2.8) | 2 (0.7) | 6 (14.0) |
 Four times | 0 (0.0) | 0 (0.0) | 1 ( 0.3) | 1 ( 2.3) |
Number of bDMARDs or tsDMARDs, mean (SD) | 1.1 (0.4) | 1.7 (0.8) | 1.6 (0.7) | 2.3 (1.1) |
Number of TNF inhibitors, mean (SD) | 0.6 (0.5) | 1.0 (0.8) | 0.9 (0.6) | 1.2 (0.7) |
Number of non-TNF inhibitors, mean (SD) | 0.6 (0.6) | 0.7 (0.6) | 0.7 (0.7) | 1.2 (1.0) |
Initial bDMARDs or tsDMARDs, n (%) | ||||
 Adalimumab | 56 (17.6) | 11 (30.6) | 76 (26.2) | 8 (18.6) |
 Etanercept | 60 (18.8) | 7 (19.4) | 57 (19.7) | 14 (32.6) |
 Golimumab | 21 (6.6) | 1 (2.8) | 28 (9.7) | 3 (7.0) |
 Infliximab | 41 (12.9) | 6 (16.7) | 61 (21.0) | 10 (23.3) |
 Abatacept | 47 (14.7) | 3 (8.3) | 39 (13.4) | 1 (2.3) |
 Rituximab | 0 (0.0) | 0 (0.0) | 1 (0.3) | 0 (0.0) |
 Tocilizumab | 93 (29.2) | 8 (22.2) | 28 (9.7) | 6 (14.0) |
 Tofacitinib | 1 (0.3) | 0 (0.0) | 0 (0.0) | 1 (2.3) |
Initial TNF inhibitor or non-TNF inhibitor, n (%) | ||||
 TNF inhibitor | 178 (55.8) | 25 (69.4) | 222 (76.6) | 35 (81.4) |
 Non-TNF inhibitor | 141 (44.2) | 11 (30.5) | 68 (23.4) | 8 (18.6) |